Company news

Alaunos Therapeutics, Inc. news in 2022

Alaunos Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

November 28, 2022

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

November 27, 2022

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

November 13, 2022

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

November 7, 2022

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

September 20, 2022

Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy

September 5, 2022

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

August 14, 2022

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

August 3, 2022

Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025

June 26, 2022

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

May 15, 2022

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

May 8, 2022

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

May 1, 2022

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

March 29, 2022

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

March 15, 2022

Calls in 2022

Decks in 2022